Flow chart of study population. IgAN ... In the present study of 93 patients with IgAN, we found that treatment with SGLT2 inhibitors (SGLT2i) for three and six months led to a notable reduction in ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

Preoperative use of SGLT2 inhibitors among patients with type 2 diabetes undergoing emergency surgery was not associated with ...

For the first time, researchers said SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin showed overall comparable effectiveness on cardiovascular outcomes in T2D.

Both SGLT2 inhibitors and GLP-1s lowered moderate or severe COPD exacerbation risk vs. DPP-4 inhibitors. Weight loss and SGLT2 inhibitors’ glucosuria effect may explain the findings. Sodium ...

The tablets, known collectively as sodium-glucose co-transporter-2 inhibitors, or SGLT2 inhibitors, are designed to lower blood sugar levels. Over four million people in the UK have been diagnosed ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs ...

SGLT2 inhibitors may have kidney- and heart-protective effects in adults with type 1 diabetes Nov 8, 2021 Sotagliflozin shows benefit for difficult-to-treat form of heart failure ...